BPAX

BioSante CEO Pleased With LibiGel Progress	Biotech Deal Activity Takes a Breather	Biotech Deals Keep Flowing, From Big Pharma to Industrials
Six Trades on FDA, Clinical Trial Binary Events	Biosante: Key Catalysts Should Renew Investor Interest	15 Biotech Stocks With the Lowest Put/Call Ratios
Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer	Is BioSante Pharmaceuticals Next in Line to Receive Institutional Praise?	BioSante Attracts Institutional Investors Ahead of Key FDA Catalysts in 2011
Life Sciences Companies Raise Record Amounts of Capital	Two Biotechs Poised for Gains as Call Options Boost Investor Sentiment	Two Small-Cap Biotechs and a Sector ETF to Keep You Afloat During the Market Correction
Top 24 Small Cap Stocks Being Chased by Smart Money	Biosante Pharma Up After FDA Announces Review of Testosterone Gel	Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder
Platform and Specialty Pharmaceutical Companies Could Strengthen in Face of Big Pharma's Patent Cliff	7 Speculative Healthcare Stocks to Rejuvenate Your Portfolio	6 Prime Biotechs for Short and Long-Term Gains
7 Dirt-Cheap Takeover Targets in Biotech	With Cancer Vaccines in Play, Will Investors Continue to Buy-In?	3 Small Cap Biotech Companies With Future Potential
3 Micro Caps With 50% Upside Potential	Upcoming PDUFA Dates for Sub-$5 Stocks	Friday Options Brief: ADM, TRW, RDWR & BPAX

Main menu